Orion Oyj ORNBV

HEL: ORNBV | ISIN: FI0009014377 12/06/2026

68,35 EUR (-1,94%)

(-1,94%) 12/06/2026

Grafiek Orion Oyj

Grafiek Orion Oyj

1 dag1d -1,94%
1 week1w -1,80%
1 maand1m -0,87%
3 maanden3m -2,77%
6 maanden6m 12,60%
1 jaar1j 8,41%
5 jaar5j 81,01%

Orion Oyj in het nieuws

Toon enkel gratis nieuws

16 juni 2026 · Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) · Persbericht

15 juni 2026 · Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) · Persbericht

11 juni 2026 · Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) · Persbericht

10 juni 2026 · Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) · Persbericht

5 juni 2026 · Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) · Persbericht

1 juni 2026 · Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) · Persbericht

30 mei 2026 · Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours · Persbericht

21 mei 2026 · Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO® Annual Meeting · Persbericht

15 mei 2026 · 105,950 Orion Corporation A shares converted into B shares · Persbericht

12 mei 2026 · Orion Animal Health receives US FDA approval for Tessie® (tasipimidine oral solution) for the treatment of noise aversion and separation anxiety in dogs · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe